Tuesday, 20 November 2012

Adding liraglutide is better than increasing insulin dose in type 2 diabetes

Liraglutide is an injectable glucagon-like-peptide-1 (GLP-1) receptor agonist that can be taken once daily to improve glycaemic control in adults with type 2 diabetes.
In a newly published study, researchers from Tianjin Medical University have shown that adding liraglutide to established insulin therapy is better than increasing the insulin dose in Chinese patients with poorly controlled type 2 diabetes and abdominal obesity.
They conducted a 12-week, randomised, parallel-group study in 84 patients who were randomly assigned to either the liraglutide-added group or the insulin-increasing dose while continuing current insulin based treatment.
 They found that addition of liraglutide to abdominally obese, insulin-treated patients led to improvement in glycemic control similar to that achieved by increasing insulin dosage, but with a lower daily dose of insulin and fewer hypoglycemic events.
Adding liraglutide to insulin also induced a significant reduction in body weight and waist circumference.
"Liraglutide combined with insulin may be the best treatment option for poorly controlled type 2 diabetes and abdominal obesity," they conclude.

Editor's note: The FDA has note potential safety concerns with liraglutide - see this NEJM summary.

Read more: Cardiovascular Diabetology

No comments:

Post a comment

Add a comment